- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic targeting of VEGF in the treatment of glioblastoma
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 16, Issue 10, Pages 973-984
Publisher
Informa Healthcare
Online
2012-08-09
DOI
10.1517/14728222.2012.711817
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
- (2017) Sith Sathornsumetee et al. NEURO-ONCOLOGY
- Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation
- (2012) Shingo Takano Brain Tumor Pathology
- Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
- (2012) V. Moreno Garcia et al. CLINICAL CANCER RESEARCH
- Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
- (2012) Annamaria Rapisarda et al. Nature Reviews Clinical Oncology
- Elevated invasive potential of glioblastoma stem cells
- (2011) Lin Cheng et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Signal transduction by vascular endothelial growth factor receptors
- (2011) Sina Koch et al. BIOCHEMICAL JOURNAL
- Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
- (2011) David A. Reardon et al. CANCER
- Bevacizumab and daily temozolomide for recurrent glioblastoma
- (2011) Annick Desjardins et al. CANCER
- Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma
- (2011) David A. Reardon et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?
- (2011) David Bruce et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- 2010 Society for Neuro-Oncology Annual Meeting: a report of selected studies
- (2011) Manmeet S Ahluwalia Expert Review of Anticancer Therapy
- The brain tumor microenvironment
- (2011) Nikki A. Charles et al. GLIA
- Use of a Mouse Model of Pancreatic Neuroendocrine Tumors to Find Pericyte Biomarkers of Resistance to Anti-angiogenic Therapy
- (2011) M. Franco et al. HORMONE AND METABOLIC RESEARCH
- Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
- (2011) John F. de Groot et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma
- (2011) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
- (2011) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
- (2011) J. Drappatz et al. JOURNAL OF NEURO-ONCOLOGY
- Annual Report to the Nation on the Status of Cancer, 1975-2007, Featuring Tumors of the Brain and Other Nervous System
- (2011) B. A. Kohler et al. JNCI-Journal of the National Cancer Institute
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2
- (2011) Jennifer Spratlin Current Oncology Reports
- Endothelial cell transdifferentiation of human glioma stem progenitor cells in vitro
- (2010) Yaodong Zhao et al. BRAIN RESEARCH BULLETIN
- Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity
- (2010) Shingo Takano et al. Brain Tumor Pathology
- A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
- (2010) Jeffrey J. Raizer et al. CANCER
- Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme
- (2010) John D. Hainsworth et al. CANCER
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Phase I Study of Vandetanib With Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma
- (2010) Jan Drappatz et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme
- (2010) James J. Vredenburgh et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
- (2010) Albert Lai et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
- (2010) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas
- (2010) Benjamin M. Ellingson et al. JOURNAL OF NEURO-ONCOLOGY
- Phase II study of sunitinib malate in patients with recurrent high-grade glioma
- (2010) B. Neyns et al. JOURNAL OF NEURO-ONCOLOGY
- Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
- (2010) Elizabeth R. Gerstner et al. JOURNAL OF NEURO-ONCOLOGY
- FDA accelerated approval benefits glioblastoma
- (2010) Timothy Cloughesy LANCET ONCOLOGY
- Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
- (2010) Lucia Ricci-Vitiani et al. NATURE
- Glioblastoma stem-like cells give rise to tumour endothelium
- (2010) Rong Wang et al. NATURE
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)
- (2010) F. M. Iwamoto et al. NEURO-ONCOLOGY
- Glioblastoma: A Method for Predicting Response to Antiangiogenic Chemotherapy by Using MR Perfusion Imaging—Pilot Study
- (2010) Rahul N. Sawlani et al. RADIOLOGY
- Antiangiogenic Therapy and Mechanisms of Tumor Resistance in Malignant Glioma
- (2010) Ruman Rahman et al. Journal of Oncology
- A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
- (2009) A. Gregory Sorensen et al. CANCER RESEARCH
- Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy
- (2009) A. K. Lucio-Eterovic et al. CLINICAL CANCER RESEARCH
- End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
- (2009) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiangiogenic therapies for high-grade glioma
- (2009) Andrew D. Norden et al. Nature Reviews Neurology
- Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging
- (2009) Ramon F. Barajas et al. RADIOLOGY
- Vascular permeability, vascular hyperpermeability and angiogenesis
- (2008) Janice A. Nagy et al. ANGIOGENESIS
- HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion
- (2008) Rose Du et al. CANCER CELL
- Adult SVZ Stem Cells Lie in a Vascular Niche: A Quantitative Analysis of Niche Cell-Cell Interactions
- (2008) Qin Shen et al. Cell Stem Cell
- New molecular targets in angiogenic vessels of glioblastoma tumours
- (2008) Joshua C. Anderson et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
- (2008) R. M. Zuniga et al. JOURNAL OF NEURO-ONCOLOGY
- VEGF Trap induces antiglioma effect at different stages of disease
- (2008) Candelaria Gomez-Manzano et al. NEURO-ONCOLOGY
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search